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Chronic radiation proctitis produces a range of clinical symptoms for which there is currently no recommended standard
management. The aim of this review was to identify the various non-surgical treatment options for the management of late
chronic radiation proctitis and evaluate the evidence for their efﬁcacy. Synonyms for radiation therapy and for the spectrum of
lower gastrointestinal radiation toxicity were combined in an extensive search strategy and applied to a range of databases.
The included studies were those that involved interventions for the non-surgical management of late radiation proctitis. Sixty-
three studies were identiﬁed that met the inclusion criteria, including six randomised controlled trials that described the effects
of anti-inﬂammatory agents in combination, rectal steroids alone, rectal sucralfate, short chain fatty acid enemas and different
types of thermal therapy. However, these studies could not be compared. If the management of late radiation proctitis is to
become evidence based, then, in view of its episodic and variable nature, placebo controlled studies need to be conducted to
clarify which therapeutic options should be recommended. From the current data, although certain interventions look
promising and may be effective, one small or modest sized study, even if well-conducted, is insufﬁcient to implement changes
in practice. In order to increase recruitment to trials, a national register of cases with established late radiation toxicity would
facilitate multi-centre trials with speciﬁc entry criteria, formal baseline and therapeutic assessments providing standardised
outcome data.
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Pelvic radiotherapy is an essential component of curative therapy
for many cancers of the urological, gynaecological and gastrointest-
inal tracts. In the treatment of pelvic malignancy there is a need to
minimise the risk of chronic radiation injury to normal tissue with-
out compromising the possibility of cure. The gastrointestinal tract
and in particular the rectum, is the site most frequently affected.
The prevalence of severe toxicity such as ﬁstulation, stricture
formation, transfusion-dependent bleeding or secondary cancers
after pelvic radiotherapy is unknown but has been estimated to
be 5% at 10 years (Nostrant, 1995) although this may be an under-
estimate (Komaki et al, 1995; Tan et al, 1997; Denton et al, 2000).
Much more common may be lesser side effects such as diarrhoea,
urgency, faecal incontinence and tenesmus which in recent studies
have been suggested to impair quality of life considerably (Koll-
morgen et al, 1994; Schultheiss et al, 1997).
Acute radiation proctitis refers to radiation-induced injury of
the rectum, during or within 3 months of radiotherapy. Chronic
radiation proctitis can continue from the acute phase or begin after
a latent period of at least 90 days (median time 8–12 months)
(Eifel et al, 1995) and may be more common in those who develop
severe acute proctitis (Denham et al, 1999), and in those with
diabetes, inﬂammatory bowel disease, hypertension or peripheral
vascular disease. Most of these risk factors have been deﬁned by
studies dependent on suboptimal assessment of rectal toxicity.
Other factors which may increase the risk of late complications
include tumour stage, and the total dose and fractionation of
radiation, although the severity of radiation damage may not be
entirely dependent on the radiation dose (Schwarchuk et al, 2000).
Whether a patient as developed chronic proctitis may be assessed
in various ways. Changes in symptoms such as irregularity of bowel
dysfunction, rectal blood loss or pain may be graded according to
criteria stated in systems such as LENT SOMA and the Franco-
Italian Glossary (Chassagne et al, 1993). The criteria for the grade
of severity varies with the scoring system used, emphasising the need
for a single universally agreed measure, but there are no described
speciﬁc radiological features which deﬁne radiation proctitis (Capps
et al, 1997). Endoscopically, proctoscopy, rigid sigmoidoscopy or
ﬂexible sigmoidoscopy may be used but it is recognised that these
different methods may not produce reproducible ﬁndings between
observers (Baron et al, 1964). Tissue biopsy may be inconclusive.
The few small longitudinal studies of ano-rectal physiological para-
meters following RT that have been published are contradictory
(Iwamoto et al, 1997; Yeoh et al, 2000).
In other inﬂammatory conditions affecting the bowel, symptoms
and measures of disease activity may correlate poorly (Yoshida,
1999) and there has been little research to determine how endo-
scopic or radiological appearances relate to bowel function.
Severe ﬁbrosis with stricturing may provide incontrovertible
evidence of radiation-induced damage but radiation-induced bowel
changes are also seen in patients without symptoms and sometimes
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www.bjcancer.comit can be hard to attribute the patients’ bowel habit directly to
physical damage caused by radiation to the rectum.
Newgastrointestinal symptomsmaybetriggeredformanyreasons.
Firstly, therefore, in the patient who has undergone radiotherapy, it
may be difﬁcult to untangle the relative contribution of psychological
and physical damage to bowel function. Secondly, when there is
severe physical radiation-induced damage present in the rectum, it
is possible that patients will also have other sites of bowel damage,
perhaps leading to bile salt or fat malabsorption. Thirdly, published
series may not represent a true cross section of irradiated patients.
There is some data suggesting that the reported number of cases with
chronic radiation proctitis and a proportion of patients who seek help
for subsequent symptoms is a fraction of the true prevalence (Yeoh
and Horowitz, 1987; Ooi et al, 1999). Experience from both oncolo-
gical and gastroenterology practice has long shown that unless
directed questions are asked and exact answers pursued that patients
may not tell their physicians about their speciﬁc gastrointestinal
symptoms, particularly if they feel the physician is not in a position
to do anything about them. The medical treatment of radiation proc-
titis is not clearly deﬁned and management is often difﬁcult. This is in
part, due to problems establishing the diagnosis and also because a
proportion of the biological changes may not be reversible.
The aim of this study was to examine systematically the non-
surgical treatments that have been proposed for this condition
and the quality of the evidence that suggests those treatments
may be efﬁcacious.
MATERIALS AND METHODS
(1) Criteria for considering studies for this review:
Types of studies
Randomised studies were included preferentially for analysis.
Conclusions from the non-randomised, non-controlled data
were drawn if there was insufﬁcient evidence from randomised
controlled trials.
Types of participants
Patients must have been diagnosed with a pelvic malignancy
and undergone pelvic radiotherapy as part of their treatment
schedule, subsequently developing radiation proctitis of any
grade, continuing from completion of radiotherapy for more
than three months, or occurring more than three months after
completion of radiotherapy.
Interventions
Studies were included which described the use of non-surgical
interventions for the treatment of late radiation proctitis and
the speciﬁc intervention was used either vs a placebo/nothing
or against other therapies.
(2) Search strategy for identiﬁcation of studies:
Concepts
(A) Synonyms for radiation therapy
(B) Synonyms for the spectrum of lower gastrointestinal
radiation toxicity
(C) Concepts A and B combined with the Boolean operator
‘AND’
A ﬁlter was not used because any type of study was considered.
This basic strategy was expanded for text and MeSH terms be-
fore being applied to a sequence of databases. Relevant studies
were identiﬁed and the inclusion criteria were then applied.
Databases
In order to be as comprehensive as possible search strategies
were employed to identify all relevant studies irrespective of
language. First, electronic databases were searched. The time
frame used was from April 2001 back to 1966 (Table 1). Sec-
ondly, reference lists of identiﬁed studies and the relevant
chapters of major oncology and gastroenterology text books
were searched. Thirdly, groups and individuals likely to hold
unpublished data were approached (Table 2).
(3) Methods of the review:
A ﬁnal list of all potential relevant articles was created in one
core database and were assessed independently by two re-
viewers to determine whether they complied with the preced-
ing inclusion criteria for this the review. Where differences
existed they were resolved by consensus and when necessary
in consultation with a third reviewer. Included studies were
graded according to the criteria used by the NHS executive
(Table 3).
(4) Statistics:
Dichotomous data is expressed as the odds ratio. Uncertainty
in each treatment is expressed using 95% conﬁdence inter-
vals (95% CI). Continuous data, i.e. symptom scores, were
converted to the weighted mean differences and an overall
weighted mean difference was calculated with standard er-
rors. The Cochrane Review Manager software RevMan 4.1
was used for estimation of overall treatment effects/meta-
analysis of results. Both ﬁxed and random effects models
were used to calculate a weighted average of the treatment
effects across the studies under review. Sensitivity analyses
as well as including study quality (quality of allocation con-
cealment) also included year of publication, the type of out-
come measures, and random and ﬁxed effects models if
appropriate.
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Table 1 Databases searched for this review
Electronic databases
1. MEDLINE – on OVID. Searched from 1966 to 2001.
2. EMBASE – on OVID. Searched from 1980 to 2001.
3. CANCERCD – on Silver Platter. Searched from 1980 to 2001.
4. Science citation index (SCI) on BIDS ISI from 1991 to 2001.
5. CINAHL – on OVID. Searched from 1982 to 2001.
6. Database of Controlled trials Register (CENTRAL/CCTR Cochrane Library 2001).
Grey Literature
1. Dissertation Abstracts – on Silver Platter. Searched from 1961 to 2001.
2. The National Health Service National Research Register – via CD-ROM March
2001.
3. Index to Scientiﬁc and Technical Proceedings (ISTP) – on BIDS ISI. 1982–4/2001.
4. SIGLE – via BLAISE Line British Libraary Current Edition.
5. Boston Spa Conferences – via BLAISE Line British Library Current edition.
6. Inside Conferences – via BLAISE Line British Library Current edition.
CCTR=Cochrane Controlled Trial Register.
Table 2 Groups and individuals contacted for further unpublished data
related to this topic
1. Individual authors of the relevant studies
2. Every member of the UK Link-Gynaecology Oncology Group
3. Every member of the EORTC Gynaecological Oncology Group
4. Letters were published in ‘Clinical Oncology’ and ‘Palliative Medicine‘ explaining the
review and requesting unpublished data
5. Gynaecological Oncology Cochrane Review group.
6. Gastroenterologists who have an interest in this ﬁeld
EORTC=European Oncology and Radiation Therapy Collaboration.
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Using the search strategy described, studies were identiﬁed, of
which 62 met the inclusion criteria, and included three randomised
controlled trials (Table 4).
Studies using anti-inﬂammatory agents
First line treatment of this condition is conventionally with anti-
inﬂammatory agents. Seven studies were identiﬁed which used such
agents. The highest level of evidence was provided by three rando-
mised controlled trials (grade IC).
Kochhar et al, 1991, Grade IC, India Radiation-induced
proctosigmoiditis. Prospective, randomised, double-blind controlled
trial of oral sulfasalazine plus rectal steroids vs rectal sucralfate
(n=37) There were 36 females treated for cervical cancer and
one male treated with prostate cancer. The mean duration from
the completion of radiotherapy was 8.3 months. Exclusion criteria
were the use of steroids in the last 2 weeks. Symptoms were
assessed using an in-house scoring system for diarrhoea, bleeding,
tenesmus and endoscopic appearance. According to the score the
cases were then graded. Baseline characteristics in both groups were
comparable. Patients were randomised to either, rectal predniso-
lone 20 mg b.d. and oral sulfasalzine 500 mg t.d.s. (n=18) or
rectal sucralfate suspension 2 g b.d. with oral placebo t.d.s. for
sulfasalzine (n=19). There were three drop-outs in the anti-inﬂam-
matory group and two in the sucralfate group. Treatment was
continued for 4 weeks.
Eight out of 15 in the anti-inﬂammatory group showed clin-
ical improvement compared to 16 out of 17 in the sucralfate
group. Seven out of 15 in this group showed endoscopic
improvement compared to 12 out of 17 in the sucralfate group,
and the degree of improvement was greater in the sucralfate
compared to the anti-inﬂammatory group. The odds ratio for
clinical improvement was 14.0 (95% CI 1.46–134.26). No
difference in endoscopic appearance was detected between the
sucralfate and the anti-inﬂammatory groups, odds ratio 2.74
(95% CI 0.64–11.76). The response was only reported for the
4 week follow-up period. There was no quality of life assess-
ment.
Rougier et al, 1992, Grade IC, France Rectites radiques: efﬁcate
comparee de deux types de corticoides adminstre localement (n=32)
(Radiation proctitis: comparing the efﬁciency of local administration
of two types of corticosteroids) There were 29 females and three
males, treated with radiotherapy for 23 gynaecological malignancies
and nine colorectal or anal tumours. All had completed radiother-
apy a minimum of 6 months ago. The diagnosis of radiation
proctitis was graded on ﬂexible sigmoidoscopy and on the degree
of bleeding. Two rectal steroid preparations were compared,
5 mg betamethasone enema b.d. (n=16) or 90 mg hydrocortisone
acetate mousse b.d. (n=16). The outcomes used were bowel activ-
ity, rectal bleeding, tenesmus with endoscopic grading. They were
assessed clinically and endoscopically at 14 and 28 days. Two
patients were lost to follow-up from the betamethasone group,
and no treatment related complications were reported.
Over the 4 weeks of treatment the endoscopic appearance
improved in a greater proportion of the hydrocortisone group
(12 out of 16) than the betamethasone group (5 out of 14), odds
ratio 5.40 (95% CI 1.12–26.05). There was no difference in the
reduction of bleeding between the hydrocortisone group (6 out
of 16) and the betamethasone group (3 out of 14), odds ratio
2.20 (95% CI 0.43–11.22). The response was only reported for
the 4 week follow-up period. Potential bias in this study includes
more severe intial disease in the betamethasone group and also that
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Table 3 Grading criteria used by the NHS Executive
The quality of the research was graded using the following criteria:
Grade I (Strong evidence)
Randomised controlled trial (RCT) or review of RCTs
IA: Calculation of sample size and accurate and standard deﬁnition of outcome
variables
IB: Accurate and standard deﬁnition of outcome variables
IC: None of the above
Grade II (Fairly strong evidence)
Prospective study with a comparison group (non-randomised controlled trial or good
observation study)
IIA: Calculation of sample size and accurate and standard deﬁnition of outcome
IIB: One of the above
IIC: None of the above
Grade III (Weak evidence)
Retrospective study
IIIA: Comparison group, calculation of sample size and accurate and standard
deﬁnition of outcome variables
IIIB: Two of the above criteria
IIIC: None of the above
Grade IV (Weak evidence
Cross sectional study
Table 4 Results of literature searches
Number Number of Number
Database source of records new records eligible
Electronic searches
MEDLINE 10 031 10 031 75
EMBASE 9983 18 0
Cancer CD 2451 0 0
Cancer CCTR 278 0 0
SCI 103 0 0
CINAHL 77 12 0
Dissertation abstracts 2 2 0
SIGLE 0 0 0
ISTP 24 24 0
Boston Spa 211 211 0
Inside Conferences 12 12 0
NRR 0 0 0
10 310 75
Results of all searches
Electronic searches Major databases 75
Grey literature 0
Handsearching Reference searching 0
Bibliographic databases 0
Personal contact 0
World Wide Web 0
Breakdown of identiﬁed references
Included RCT
Intervention studies studies Non-RCT Excluded
Anti-inﬂammatories 8 3* 5 2
SCFA enemas 5 2 3 1
Sucralfate 8 1* 7 3
Thermal therapy 16 1 15 3
Formalin 15 0 15 1
Hyperbaric oxygen 9 0 9 0
Dilators 3 0 3 2
*Kochhar et al, 1991 is cited twice as an RCT in the anti-inﬂammatory and sucralfate
sections. CCTR=Cochrane Controlled Trial Register; ISTP=Index to Scientiﬁc and
Technical Proceedings; NRR=NHS National Research Register; SCI=Science Cita-
tion Index; SIGLE=Electronic database for grey literature – BLAISE Line British
Library.
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compared with 2 out of 16 in the hydrocortisone group. There
was no quality of life assessment.
Cavcic et al, 2000, Grade IC, Croatia Metronidazole in the
treatment of chronic radiation proctitis: clinical trial (n=60) Sixty
patients with rectal bleeding and diarrhoea were allocated to treat-
ment with metronidazole (36400 mg orally per day), mesalazine
(361 g orally per day), and betamethasone enema (daily) or mesa-
lazine and betamethasone enema, but without metronidazole, for 1
year. The efﬁcacy of metronidazole was assessed on the basis of
rectal bleeding, diarrhoea, and rectosigmoidoscopy in all patients.
The incidence of rectal bleeding and mucosal ulcers was signiﬁ-
cantly lower in the metronidazole group at 4 weeks (P=0.009), 3
months (P=0.031), and 12 months (P=0.029). There was also a
signiﬁcant decrease in diarrhea and oedema in the metronidazole
group, after 4 weeks of treatment (P=0.044), 3 months
(P=0.045), and 12 months (P=0.034). One year after treatment,
22 out of 24 of the metronidazole group demonstrated a reduction
in the grade of their rectal bleeding compared to 5 out of 12 in the
group treated with mesalazine and betmethasone, odds ratio 15.40
(95% CI 2.43–97.68). Similarly 23 out of 24 in the metronidazole
group compared to 8 out of 12 had experienced reduction in their
diarrhoea and rectal erythema, odds ratio 11.50 (95% CI 1.11–
118.71). The rectal ulceration at 1 year had decreased in 22 out
of 24 of the metronidazole group compared with 7 out of 12 of
the group treated with anti-inﬂammatories alone, odds ratio 7.86
(95% CI 1.24–49.84). No side effects were reported.
Other studies In addition, four non-randomised studies were
identiﬁed. One prospective cross-over trial of six patients, 5ASA
enemas vs betamethasone enemas, showed no signiﬁcant beneﬁt
for either treatment (Triantiﬁllidis et al, 1990). Three series
reported the effect of various anti-inﬂammatory agents: sulfasala-
zine enemas nightly for 2–6 months in a group of four patients
(Baum et al, 1989) were not effective. Oral sulfasalazine, for 1 year,
in a group of four patients (Goldstein et al, 1976) demonstrated an
improvement from the baseline symptoms as did daily oral oestro-
gen and norethisterone for 1 month in one case of refractory
radiation proctitis (Wurzer et al, 1998).
Studies using SCFA enemas
Short chain fatty acids (SCFA) are the main oxidative fuel of colo-
nic mucosa and their use may be impaired in chronic radiation
proctitis. SCFA are predominantly produced in the colon by anae-
robic bacterial fermentation of non-absorbed carbohydrates, in
dietary ﬁbre. Butyric acid is the most important. SCFA also exert
a trophic effect on the colonic mucosa by stimulating the physio-
logical pattern of proliferation and promoting cellular
differentiation. In the setting of radiation induced ischaemia, the
associated mucosal atrophy may interfere with mitochondrial fatty
acid oxidation so supplementation of SCFA in the form of enemas
could overcome this deﬁciency and improve the energy supply to
colonocytes. Moreover, the dilator effect of SCFA on arteriolar
walls may improve mucosal blood ﬂow. Five reports of four studies
were identiﬁed in this section. Two were randomised studies.
Talley et al, 1997, grade IC (Australia) Short-chain fatty acids
in the treatment of radiation proctitis: a prospective randomised,
double-blind, placebo-controlled, cross-over pilot trial (n=15) Two
females and 13 males; 12 prostate, one cervix and two rectum, trea-
ted with pelvic radiotherapy a mean period of 12.2 months earlier
were assessed using an in-house symptom score (six items: rectal
pain, rectal bleeding episodes, quantity of blood, days of diarrhoea,
number of stools and urgency). Endoscopic and histological scores
were also calculated. The patients were randomised to receive
either a normal saline placebo enema or a 60 ml enema containing
40 mM of butyrate administered twice a day. Each treatment was
prescribed for 2 weeks with a 1 week washout period between
treatments. Three patients failed to complete the course. The total
symptom score at baseline ranged from 2–11 (median 5.5). There
was a non-signiﬁcant improvement in symptom scores on the
active treatment, mean score 3.5 (range 3–5) compared with 4.5
mean score (range 3–6) for those receiving placebo. The results
are published in the form of the median value (plus interquartile
range) for the average placebo period and active period and the
raw data is required from the authors before the results can be
dichotomised. There was no quality of life assessment.
Pinto et al, 1999, grade IC, (Portugal) Short chain fatty acids
are effective in short term treatment of chronic radiation proctitis.
Randomised, prospective double blind, controlled trial (n=19) Nine-
teen patients (one male and 18 females) with grade III chronic
radiation proctitis were randomised to SCFA enema, 60 ml b.d.
for 5 weeks (n=10) or a placebo (n=9). Baseline characteristics of
each group were comparable. The speciﬁc outcome variables moni-
tored for a period of 6 months were: adverse effects, number of
days of rectal bleeding in the previous week and haemoglobin.
The endoscopic appearance was scored for: hyperaemia and
neovascularisation, friability, oedema and erosions by two indepen-
dent assessors who were blinded to the treatment. Biopsies for
mucosal DNA and protein content were also measured.
One patient from the SCFA arm and two from the placebo arm
did not complete the trial. At 5 weeks the patients treated with
SCFA had a signiﬁcant reduction (4.4 to 1.4) in the number of
days per week of rectal bleeding (P=0.001) whereas in the placebo
group it fell from 5.1 to 3.4 (P=0.12). Haemoglobin levels at the
end of the treatment period were higher in the SCFA group,
13.1+0.9 vs 10.7+2.1 g dl
71 (P=0.02) and the endoscopic scores
had decreased signiﬁcantly in both groups but were signiﬁcantly
lower in the SCFA group (P=0.02). Changes in DNA and protein
concentration decreased in both groups but signiﬁcantly more so
in the placebo treated group (P=0.05). In long term follow-up
two patients failed to complete the course from the placebo group
because of severe bleeding leaving nine in the SCFA arm and ﬁve
in the placebo group. At the end of the 6 months the endoscopic
score was similar in the two groups. No adverse events related to
either of the groups were noted and there was no quality of life
assessment. As a consequence of the way the data has been
reported we have presented this data as a weighted mean difference
(WMD) which for endoscopic scores was 1 (72.33 to 4.33), a
statistically non-signiﬁcant difference between SCFA and placebo.
For the number of days of rectal bleeding per week at the end of
the treatment period the WMD was 72( 74.4 to 70.4), again
a statistically non-signiﬁcant difference, but perhaps showing a
trend to less days of rectal bleeding with the SCFA enema.
Other studies In addition, two non-randomised series were
identiﬁed. Mamel et al (1995) (IIIC), in an open study of six cases
using SCFA reported a signiﬁcant improvement in clinical and
mucosal response although this is not statistically assessed. Al-
Sabbagh et al (1996) (IIC) in their prospective pilot study of seven
cases demonstrated a signiﬁcant improvement for rectal bleeding
but not endoscopic appearances. The duration of the response is
not stated other than for the treatment period of 4 months in
Al-Sabbagh et al (1996). No toxicity was reported in any of the
studies. Quality of life data were not presented.
Although there were two trials in this category using the same
intervention against a placebo, they are not directly comparable
due to differences in the outcome measurements and method of
data presentation. Talley et al (1997) was a cross-over study and
used a cumulative score encompassing the number of episodes of
rectal bleeding per week. Pinto et al (1999) recorded the number
of days on which rectal bleeding occurred. Although both sets of
cases were scored endoscopically, this is not on the same scale so
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the different scales, because of the absence of individual patient
data we were unable to dichotomise and combine the data. Talley
et al (1997) reported no beneﬁt from the use of SCFA (but the
treatment period of 2 weeks was short), and Pinto et al (1999) also
reported no signiﬁcant improvement either endoscopically or on
rectal bleeding. It is not surprising that neither of these trials
yielded any signiﬁcant results. These numbers are small for any
type of study but especially for prospective, randomised ones and
therefore statistically underpowered.
Studies using sucralfate and pentosan polysulphate
Sucralfate is a highly sulphated polyanionic dissacharide. In this
setting, its postulated mechanisms of action include stimulation
of epithelial healing and the formation of a protective barrier.
Pentosan polysulphate (PPS) is a synthetic derivative of a glycosa-
minoglycan which is present in the surface of the bladder, vessels
and the gastrointestinal tract lining. The ability of PPS to reduce
epithelial permeability and prevent adherence has been extrapo-
lated to the large bowel. Eight relevant references were identiﬁed
addressing the effect of these agents in chronic radiation proctitis.
One is a RCT, two prospective open studies, and four studies
describe the effect of rectal sucralfate in case reports or small series
with one report of the effect of oral sucralfate.
Kochhar et al, 1991, Grade IC, India Radiation-induced proc-
tosigmoiditis. Prospective, randomised, double-blind controlled trial of
oral sulfasalazine plus rectal steroids vs rectal sucralfate (n=37) The
strongest evidence for the use of sucralfate comes from the
evidence presented in this trial, which compares the use of anti-
inﬂammatories with rectal sucralfate. Criticisms of this study are
that the allocation concealment is not clear and there is no expla-
nation for those cases lost to follow-up. The endpoints used to
evaluate response, i.e. scores for clinical and mucosal effect, are
useful and show that the odds ratio for the beneﬁcial effect of
sucralfate on clinical outcomes is 14.0 (95% CI 1.46–134.26)
and 2.74 (95% CI 0.6–11.75) for mucosal response. The duration
of follow-up was only 4 weeks.
Other studies In addition seven non-randomised studies were
identiﬁed. In two prospective studies Kochhar et al (1999),
followed 26 cases treated with rectal sucralfate, and Grigsby et al
(1990) described 13 cases treated with oral PPS, IIC. Both are well
conducted with deﬁnitive outcomes of response and show a beneﬁt
for the use of rectal sucralfate for a period of 4 months and oral
pentosan for 1 year, respectively. Of the retrospective reports (four
describe the use of rectal sucralfate as a case report (Kochhar et al,
1988), and series of three, eight and three patients respectively
(Ladas and Raptis, 1989; Kochhar et al, 1990; Stockdale and Biswas,
1997). All showed a beneﬁt in both clinical and mucosal outcome,
although the majority of these were not graded or scored to
demonstrate signiﬁcant differences. One report outlines the beneﬁ-
cial effect of oral sucralfate in established chronic radiation proctitis
in three isolated cases for a minimum of 3 years (Sasai et al, 1998).
Morbidity related to sucralfate was not reported and there was one
case of a rash with oral pentosan. The treatment intervals were
generally short and none provide any quality of life data.
Formalin therapy
In radiation proctitis, vascular telangiectasia and non-healing
mucosal ulceration, perhaps due to an underlying obliterative
arteritis, may lead to severe recurrent haemorrhage. Formalin
may sclerose and seal fragile neovasculature in radiation
damaged tissues preventing further bleeding. Application directly
to the mucosa produces local chemical cauterisation. It can stop
bleeding by sealing the neovascularised telangiectatic spots and
ulcers. The success of bleeding control is related to the accurate
localisation and application of formalin to all the affected
points.
We identiﬁed 15 references relating to the use of rectal formalin.
Three were prospective case series (level IIC evidence) and 12 were
retrospective reports (level IIIC). These reports are quite heteroge-
nous (Table 5). None used a control group or quoted any quality
of life data. The severity of radiation proctitis is graded in only one
report. The technique and the concentration of formalin used vary.
The two main approaches use irrigation of formalin (ﬁve reports),
either 3.6% formalin solution (n=2) or 4% formalin solution
(n=3). The other method (described in 10 reports) is the direct
application of gauze soaked in formalin, and although most reports
used 4% formalin (n=9) there was one report that used 10% solu-
tion. None of the reports used an objective scoring system to assess
the response to treatment, but two reports described the effect in
terms of changes of haemoglobin level. The remainder described
the response in terms of the transfusion requirements or the effect
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Table 5 Results of formalin reports
Level of % Formaline Resp rate Duration
Reference evidence technique n % CR of response Morbidity QOL Mortality
Rubinstein et al, 1986 IIIC 3.6% – irrigation 1 100 14 months 0 0 0
Reimer et al, 1987 IIIC 3.6% – irrigation 2 100 14 months 0 0 0
Seow-Choen et al, 1993 IIIC 4.0% – direct 8 100 6 months 1 (stricture) 0 0
Isenberg et al, 1994 IIIC 4.0% – direct 2 100 3 months 0 0 0
Correia et al, 1994 IIIC 4.0% – irrigation 14 64% CR 6 months 0 0 0
21% PCR
Mathai and Seow-Choen, 1995 IIIC 4.0% – direct 29 75 12 months 1 (stricture) 0 3-cancer
Biswal et al, 1995 IIIC 4.0% – direct 16 81 11 months 0 0 0
Chapuis et al, 1996 IIC 4.0% – direct 14 71 3 months Not clear 0 0
Sacclarides et al, 1996 IIIC 4.0% – irrigation 16 81 not stated 4 anal ulcers 0 0
Roche et al, 1996 IIIC 4.0% – direct 6 100 12 months 0 0 0
Faragher and Bailey, 1997 IIIC 10.0% – direct 7 100 not stated 1 (anal pain) 0 0
Goldinger, 1998 IIIC 4.0% – direct 1 100 not stated 0 0 0
Yegappan et al, 1998 IIC 4.0% – direct 55 89 not stated 0 0 0
Counter et al, 1999 IIC 4.0% – irrigation 11 67 20 months 2 incont, 1 anal
sten, 1 ulcer
Coyoli et al, 1999 IIIC 4.0% – direct 7 86 17 months 1 bleeding sten 0 0
CR=complete response (a complete response is the conﬁrmed resolution of the initial features determined at a speciﬁc interval); incont=incontinence; n=number of cases;
PR=partial response (a partial response is a 50% reduction in the initial features determined at a speciﬁc interval); QOL=quality of life; resp rate=response rate; sten=stenosis.
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reports.
In summary, 208 patients were described with a mean follow-up
of 6 months. In each of the reports there appeared to be beneﬁt
from the use of formalin in chronic haemorrhagic proctitis, but
this may be subject to reporting bias. Serious side effects were
reported in 11 patients with ﬁve cases of anal ulceration, two rectal
strictures, two patients with faecal incontinence and two with anal
pain. Minor side effects were not frequently reported. Duration of
effect cannot be assessed reliably from the data available but
appears to be a minimum of 3 months. The absence of quality
of life data means the impact of this treatment from the patient’s
perspective cannot be addressed.
Thermal coagulation therapy
Endoscopic coagulation with a variety of devices has been reported
to be effective for the control of radiation-induced bleeding. The
technique generally used is coagulation of focal bleeding telangiec-
tasia rather than the entire friable mucosa. Several treatment
sessions are often required. Scarring and re-epithelisation with
more normal tissue tend to occur over time.
Sixteen relevant studies were identiﬁed. Apart from one RCT
and one prospective series the remaining 14 are retrospective series
or reports. Although these case series all refer to the use of abla-
tive therapy in late radiation proctitis, different types of
coagulation probes or lasers are described. Eight look at the use
of the YAG laser, four at Argon lasers, three at bipolar cautery
and two at heater probes. The results of these studies are described
in Table 6.
Jensen et al, 1997, (USA) grade IC A randomised prospective
study of endoscopic bipolar electrocoagulation and heater probe
treatment of chronic rectal bleeding from rectal telangiectasia
(n=21) Selection criteria included pelvic RT at least 2 years
earlier, rectal bleeds at least three times per week, anaemia, having
failed 1 year of medical therapy and consideration for surgery, and
a life expectancy of 2 years. Chronic radiation proctitis was
conﬁrmed endoscopically but not graded in 21 cases (18 with
carcinoma of the prostate and three with cervical cancer). Patients
were randomised to treatment with a heater probe (n=9) or a
bipolar electrocoagulation probe (n=12). Treatment sessions were
repeated with the same probe till the bleeding resolved and a mean
of four sessions per case were administered for both probes. The
physicians who subsequently assessed the patients were blinded.
All other treatments were discontinued. Assessment was repeateded
every 4–6 weeks until bleeding stopped and then every 4–6
months for 1 year. If new telangiectasia were noted they were
retreated by the same probe.
In both the bipolar probe and the heater probe the mean fall in
severe bleeds per case was statistically signiﬁcant at P50.05. In the
12 months of endoscopic treatment vs 12 months medical therapy
the severe bleeding episodes (deﬁned as a bleed provoking and
unscheduled hospital assessment) diminished signiﬁcantly for the
bipolar probe (75 vs 33%) and heater probe (67 vs 11%). The
weighted mean difference did not show a signiﬁcant difference
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Table 6 Results of reports for the effects of thermal therapy in late radiation proctitis
YAG laser
Author Power Response rate
Duration
(months) Side effects (SE)
Chapuis et al, 1996 40 W 30/34 6–64 4 mucous discharge, 1 acute
prostatitis, 1 rectal structure
Leuchter et al, 1982 60 W 1/1 CR 24 None
Alqhuist et al, 1986 30–40 W 2/4 CR 12 1 tenesmus
Alexander and Dwyer, 1988 80–90 W 6/8 21 3 ileus, 1 abdominal pain
Jacobs, 1989 NA 2/2 12 NA
Lucarotti et al, 1991 80 W 5/5 18 NA
Carbatzas et al, 1996 20–30 W 6/9 PR 24 NA
Taylor et al, 2000 4–10 W 15/23 6 2 rectal ulcers
Argon Laser
Author Flow rate Power RR Duration
(months)
SE
Buchi and Dixon, 1987 1.5–2.5 ml s
71 3.5 W and 7–8 W 3/3 6 1 had cramps
O’Connor, 1989 0.5 pulses 1.5 W 5/5 5 None
Taylor et al, 1993 1.5–2.5 ml s
71 3.5 W and 7–8 W 14/14 22 None
Silva et al, 1999 1.5 l min
71 50 W 26/28 10 None
Fantin et al, 1999 3 l min
71 60 W 7/7 18 None
Kaassis et al, 2000 0.6 l min
71 40 W 16/16 PR 10 None
Tam et al, 2000 2.0 l min
71 60 W 15/15 PR 24 2 rectal strictures
Bipolar and heater probe
Author Modality Power RR Duration SE
Fuentes et al, 1993 Heat probe 20 J pulse
71 8/8 NA None
Mannoury et al, 1991 Bipolar setting 5, 2 s pulses 4/4 9/12 None
Haulk, 1996 Bipolar 2–5 W or 11–25 W 8/8 4/12 None
Jensen et al, 1997 Heat probe 10–15 W, 1 s pulses 12/12 24/12 None
Bipolar 10–15 J 9/9 24/12 None
CR=complete response; J=Joules; L=Litres; min=minutes; NA=not available; PR=partial response; RR=reponse rate; s=seconds;
W=Watts.
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reduction in the units of blood transfused per case pre- and
post-treatment was only statistically signiﬁcant in the group treated
with the heater probe and the weighted mean difference reﬂected
this (73.2; 95% CI 74.58 to 71.82). The increase in the haema-
tocrit compared with the baseline was statistically signiﬁcant for
both groups and comparing the effects of the two groups the
weighted mean difference favoured the heater probe (72.90;
95% CI 75.22 to 70.58). During follow-up endoscopy there
was resolution of the telangiectasia, scarring or epithelial replace-
ment in all cases in both groups. Patient interviews before, and 6
months after treatment revealed that rectal bleeds, tenesmus and
their general health had improved. There were no recorded side
effects.
Other studies None of the references in this section state the
grade of the proctitis and one study (Silva et al, 1999) uses a
formal score to quantify rectal bleeding pre- and post-treatment
allowing an objective comparison to be conducted. Generally,
outcome assessments used are presence or absence of bleeding,
control of bleeding, haemoglobin pre- and post-treatment and
transfusion requirements. The point at which transfusion occurs
is rarely described making transfusion requirements and haemoglo-
bin values relative measures. The impression is that thermal
coagulation therapy has a useful role in haemorrhagic radiation
proctitis that is refractory to other medical treatments. This cannot
be statistically supported because of the quality of the reports and
the size of the trials.
Hyperbaric oxygen therapy
Hyperbaric oxygen therapy (HBO) has an angiogenic effect and has
been shown to cause an eight- or nine-fold increase in the vascular
density of soft tissues over air-breathing controls. The subacute and
chronic phases of radiation wounds are particularly suited to this
form of therapy. HBO acts to stimulate collagen formation at the
wound edges through elevation of local tissue oxygen tensions.
New microvasculature dependent on collagen matrix, is greatly
enhanced in this setting and allows re-epithelialisation to occur.
Nine relevant references were identiﬁed, reporting treatment in
86 cases that were followed up for a mean period of 15 months
(Table 7). Eight were retrospective series or reports and there
was only one prospective observational case series (Williams et
al, 1992: level IIC). All of these reports were case series with
heterogeneous characteristics. In only two of these reports (Feldme-
ier et al, 1996; Gouello et al, 1999) were there full baseline
assessments of the degree of chronic radiation proctitis with a score
or a grade of the histological or symptomatic features. Also the
pressures of HBO and duration of the treatment sessions varied.
The number of treatments depended on degree of the lesion.
Assessment of response was usually with a vague description of
the resolution of symptoms but not parameters that could be
scored and used for statistical analysis. The duration of response
was inconsistently recorded. Quality of life data was not recorded
in any report. Side effects were reported in eight cases but were
largely transient, minor and related to aural barotrauma. Therefore,
although the impression is that HBO may be of value for large
bowel chronic radiation changes that are refractory to other treat-
ments, the degree of beneﬁt and the cumulative effect or duration
of response cannot be quantiﬁed because of the methodology and
quality of the data.
Miscellaneous interventions
Oxidative stress is thought to be a major mechanism in the devel-
opment of chronic radiation proctitis and agents with anti-oxidant
properties have been used in an attempt to limit tissue damage in
radiation injury. We identiﬁed one series investigating the effect of
vitamins C and E in the treatment of 10 cases with established
chronic radiation proctitis who presented with one or more symp-
toms including rectal bleeding pain urgency or tenesmus. The
severity and frequency of symptoms and a score of the lifestyle
impact were used to assess response before and after treatment
for 1 year and all reported a sustained improvement in their initial
symptoms without side effects (Kennedy et al, 2001).
Strictures of the rectosigmoid junction and rectum are a recog-
nised consequence of late radiation damage. The narrowing results
in acute or episodic periods of large bowel obstruction, often
decades after the original radiation therapy. Non-surgical dilatation
has been attempted. Three relevant studies were identiﬁed and
included two case reports of the use of a dilator (Triadaﬁlopoulos
and Sarkisian, 1990) or stent (Yates and Baron, 1999) and one
series of four cases which were endoscopically dilated (Johansson,
1996). Although the strictures are described they are not scored
and the absence of a formal baseline assessment and objective
response means that the effect which appears to be beneﬁcial in
each report cannot be quantiﬁed, nor can the duration of response
be determined from the data available. Side effects include one case
of brief post dilatation bowel pain and another case of perforation.
Quality of life issues are referred to in one report where the
patients’ general health was felt to improve as a result of the treat-
ment (Yates and Baron, 1999).
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Table 7 Hyperbaric oxygen results
Author n HBO details Follow-up Response rate Side effects
Charneau et al, 1991 1 2.5 ata, 82 tx, 90 min b.d. 11 months 1 PR None
Williams et al, 1992 3 2 ata, mean 44 tx, 90–120 min 36 months 2 PR 1 perforated ear drum
Nakada et al, 1993 1 20 ata, mean 30 tx, 90 min 7 months 1 PR None
Feldmeier et al, 1996 7 2.4 ata, mean 30 tx, 90 min NA 4 PR None
Warren et al, 1997 14 2 ata, mean 40 tx, 90 min 14 months 8 CR None
1P R
Woo, 1997 18 2 ata, mean 24 tx, 105 min 5 visual trauma
1 aural trauma
1 angina
Gouello et al, 1999 36 2.5 ata, mean 40 tx 90 min 12 months 9 CR None
12 PR
Kitta et al, 2000 4 2 ata, mean 45 tx, 60 min 3 months 1 CR None
3C R
Bem et al, 2000 2 NA 10 months 2 CR None
ata=atmospheres of pressure; b.d.=twice a day; CR=complete response; HBO=Hyperbaric oxygen; n=number of cases;
NA=not available; PR=partial response; tx=treatment sessions.
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This review of the literature for non-surgical interventions for the
management of late radiation proctitis has identiﬁed a number of
treatment approaches supported by varying levels of evidence. Six
controlled studies are reported, three relate to the comparison of
different rectal steroid preparations and the comparison between
anti-inﬂammatory agents and rectal sucralfate, two use short chain
fatty acid enemas and one contrasts the effect of bipolar electrocoa-
gulation vs the heater probe. These show that the use of sucralfate
may be better than anti-inﬂammatory agents, which in turn may
have greater effect if used with metronidazole. Rectal hydrocorti-
sone may be better than betamethasone.
The reports describe slightly different interventions and outcome
parameters so that they cannot be compared and a summary statis-
tic cannot be derived. Ironically the wealth of case series although
of interest, can only give an impression of effect and cannot be
collectively summarised to produce a cumulative response rate or
duration of effect. The overwhelming feature of the data presented
here is that the majority of references describe one individual’s or
one centre’s experience of a speciﬁc intervention administered
without comparison to a control or another agent. In many cases,
it is not clear how extensively patients have been investigated and
whether other causes for their symptoms have been excluded. The
reasons for the paucity of controlled studies may relate to the rela-
tive rarity of late radiation proctitis and the logistic difﬁculties that
exist in compiling a series large enough to be randomised between
therapies.
There were a number of speciﬁc problems with the details avail-
able in many of the identiﬁed reports. First, few background details
were available with particular respect to the tumour stage and
radiation details. Secondly, the method of determining the diagno-
sis was only occasionally documented. Late radiation proctitis may
be less easy to grade accurately on rigid sigmoidoscopy compared
to ﬂexible sigmoidoscopy and there is also anecdotal evidence that
some of the bowel preparations commonly used for ﬂexible endo-
scopic examinations may exacerbate the changes seen. None of the
endoscopic scoring systems take these factors into consideration
but clearly the mode of assessment needs to be recorded for subse-
quent comparisons. Thirdly, there was rarely a formal baseline
assessment of the symptoms and where this was stated the scoring
systems were often different so that the grade could not be used as
a comparison with other cases. Fourthly, the outcome measures,
where used, were variable as was the scoring of the response when
performed. The duration of the responses and the side effects of
treatments were not always stated. Quality of life scores either
before or after the intervention were hardly ever recorded. Dete-
rioration in presenting symptoms may not always relate to
failure of the intervention but may be a consequence of tumour
or disease progression although this is often difﬁcult to determine
as the two scenarios are often indistinguishable. Therefore speciﬁc
details regarding the method of ascertaining a failed response need
to be stated. Finally, interventions were not standardised so that
there were substantial variations in dose and administration. These
combined factors serve to produce a very heterogeneous cohort of
reports that cannot be scored or graded to produce subclasses and
objective response rates unless more information is available. A
proposed scheme to address all these issues might include:
(1) A detailed account of the determination of the diagnosis
including background details such as precise radiation prescrip-
tion and absence of infection.
(2) Scored symptoms as in Ulcerative Colitis (UC) with the Colitis
Activity Index (Rachmilewitz, 1989) or the Ulcerative Colitis
Scoring System (Schroeder et al, 1987), before and after the
speciﬁc intervention.
(3) Scored endoscopic appearance (as for UC e.g. Baron score
(Baron et al, 1964) and the Colitis Endoscopic index
(Rachmilewitz, 1989)), before and after the speciﬁc intervention.
(4) Scored histological assessment (as for UC) which should be
standardised.
The outstanding issue is the degree to which radiation induced
damage to the rectum contributes to symptoms in this group of
patients and how much comes from residual tumour, psychological
factors, co-incident small intestinal damage or other changes within
the abdomen and pelvis outside the bowel. Some of the areas that
need to be addressed include:
(1) How should late radiation proctitis be staged and how should
endoscopic, radiological, physiological and quality of life
assessments be combined to assess the patient’s needs best?
(2) Who needs intervention?
(3) What treatments are effective?
(4) Is there an optimal step up treatment approach?
(5) How should patients be followed up after treatments, how long
for and what parameters should be measured subsequently?
Implications for practice and research
If the management of late radiation practice is to become evidence
based then good quality placebo-controlled studies need to be
conducted to support the treatment options recommended. This
review suggests that late radiation proctitis is not reported very
often by patients to the clinicians who deliver the pelvic radiother-
apy and as a result a number of fundamental issues remain to be
clariﬁed. First, the true incidence of the disease is not clear. There-
fore, physicians caring for patients who have undergone pelvic
radiotherapy need to be more aware that this group may develop
problematic symptoms which may need detailed questioning to
elicit and which may require specialist gastroenterological assess-
ment to characterize in detail. Secondly, there is an urgent need
to deﬁne clearly the diagnostic criteria and a uniﬁed grading
system by which late radiation proctitis can be categorised. With-
out such a system, it is unlikely that meaningful randomised
studies, particularly in a multi-centre setting, can be designed.
We propose that cases should be enrolled into regional or
centralised registers of radiation toxicity or that all such patients
should be referred to regional centres with an interest in radia-
tion-induced gut toxicity. In this way terminology, baseline
assessments including comorbidity and the documentation of ther-
apeutic effect could be standardised. Interventions could be
randomised and outcome data could be pooled to assess the
response to treatment objectively. This approach would provide
an evidence base of results of different treatments to develop an
integrated care pathway for this difﬁcult condition.
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